Возможности химиотерапии у больных местно-распространенным и метастатическим аденогенным раком поджелудочной железы

В настоящее время рак поджелудочной железы остается одной из наиболее неблагоприятных опухолевых патологий, характеризующейся выраженными сложностями диагностики и лечения, значительным влиянием на трудоспособность и качество жизни больных, низкими показателями продолжительности жизни пациентов. Особенности развития злокачественных новообразований данной локализации способствуют ограничению возможности выполнения радикального оперативного вмешательства, в связи с чем особая роль в лечении больных раком поджелудочной железы отводится химиотерапии. Специфическая системная лекарственная терапия при данной патологии является важнейшим и, в преобладающем числе случаев, обязательным элементом лечения. Она может осуществляться в неоадъювантном, адъювантном и самостоятельном режиме, включать моно- или поликомпонентные схемы, а также сочетаться с другими видами системного или локального противоопухолевого воздействия. Выбор режима химиотерапии зависит в первую очередь от общего соматического статуса пациента и определяется потенциальной токсичностью той или иной комбинации цитостатиков. В данном обзоре литературы продемонстрирована эффективность применения различных схем химиотерапии у больных раком поджелудочной железы III–IV стадии в рамках первой и второй линии, описаны частота возникновения нежелательных реакций на лечение и их характер, упомянуты пути снижения степени токсичности поликомпонентных режимов лекарственной терапии. Данный обзор выполнен на основании анализа научных источников интернет-ресурса «National Center for Biotechnological Information».

1. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21;24(43):4846–4861. https://doi.org/10.3748/wjg.v24.i43.4846

2. Состояние онкологической помощи населению России в 2018 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П.А.Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019, 236 с.

3. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013 Sep;63(5):318–348. https://doi.org/10.3322/caac.21190

4. Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017 Dec;6(6):58. https://doi.org/10.21037/cco.2017.12.04

5. Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019 Aug 8;14(1):141. https://doi.org/10.1186/s13014-019-1345-6

6. Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci. 2019 Sep 13;20(18):4543. https://doi.org/10.3390/ijms20184543

7. Милешина С.Е. Противоопухолевые средства. Доступно по: http://do.rsmu.ru/fileadmin/user_upload/pf/protivoopukholevye_sr-va.pdf Дата обращения: 21.06.2020.

8. Покатаев И.А., Алиева С.Б., Гладков О.А., Загайнов В.Е., Кудашкин Н.Е., Патютко Ю.И. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2019;3s2(9):456–468. https://doi.org/10.18027/2224-5057-2019-9-3s2-456-468

9. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. https://doi.org/10.1200/JCO.1997.15.6.2403

10. Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017 Jun 22;18(7):E1338. https://doi.org/10.3390/ijms18071338

11. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640–1648. https://doi.org/10.1200/JCO.2012.43.3680

12. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212–2217. https://doi.org/10.1200/JCO.2006.09.0886

13. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513–5518. https://doi.org/10.1200/JCO.2009.24.2446

14. Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, et al. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore). 2017 Jan;96(1):e5702. https://doi.org/10.1097/MD.0000000000005702

15. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 Aug 20;24(24):3946–3952. https://doi.org/10.1200/JCO.2005.05.1490

16. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778–3785. https://doi.org/10.1200/JCO.2008.20.9007

17. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15;22(18):3776–3783. https://doi.org/10.1200/JCO.2004.12.082

18. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CAL-GB 80303). J Clin Oncol. 2010 Aug 1;28(22):3617–3622. https://doi.org/10.1200/JCO.2010.28.1386

19. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960–1966. https://doi.org/10.1200/JCO.2006.07.9525

20. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817– 1825. https://doi.org/10.1056/NEJMoa1011923

21. Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016 Jun;17(6):801–810. https://doi.org/10.1016/S1470-2045(16)00172-8

22. JG, de Jesus VHF, Camandaroba MPG, Dettino ALA. Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. Ther Adv Med Oncol. 2019;11:1-13. https://doi.org/10.1177/1758835919874650

23. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013 Jan 1;31(1):23–29. https://doi.org/10.1200/JCO.2012.44.4869

24. Wang Z-Q, Zhang F, Deng T, Zhang L, Feng F, Wang F-H, et al. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond). 2019 08;39(1):26. https://doi.org/10.1186/s40880-019-0367-7

25. Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, et al. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol. 2018 Nov 15;10(11):421– 430. https://doi.org/10.4251/wjgo.v10.i11.421

26. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369

27. Tsujimoto A, Sudo K, Nakamura K, Kita E, Hara R, Takayama W, et al. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Sci Rep. 2019 07;9(1):16187. https://doi.org/10.1038/s41598-019-52486-x

28. Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, et al. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol. 2019 Oct;10(5):910–917. https://doi.org/10.21037/jgo.2019.06.02

29. Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J Cancer. 2019;10(18):4420–4429. https://doi.org/10.7150/jca.29898

30. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, et al. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 Aug;9(15):5406–5415. https://doi.org/10.1002/cam4.3229

31. Charton E, Bachet J-B, Hammel P, Desramé J, Chibaudel B, Cohen R, et al. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. Cancer Med. 2019 Sep;8(11):5079–5088. https://doi.org/10.1002/cam4.2311

32. Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D. Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol. 2018 Aug;144(8):1503–1507. https://doi.org/10.1007/s00432-018-2666-9

33. Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014 Sep 9;111(6):1132–1138. https://doi.org/10.1038/bjc.2014.418

34. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 25;381(4):317– 327. https://doi.org/10.1056/NEJMoa1903387

35. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676–1681. https://doi.org/10.1016/j.ejca.2011.04.011

36. Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545– 557. https://doi.org/10.1016/S0140-6736(15)00986-1

37. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423–2429. https://doi.org/10.1200/JCO.2013.53.6995

38. Lee MG, Lee SH, Lee SJ, Lee YS, Hwang J-H, Ryu JK, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy. 2013;59(4):273–279. https://doi.org/10.1159/000356158

39. Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80(5–6):301–306. https://doi.org/10.1159/000329803

40. Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol. 2019 Nov 15;11(11):1021–1030. https://doi.org/10.4251/wjgo.v11.i11.1021

41. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009 Jan;63(2):313–319. https://doi.org/10.1007/s00280-008-0741-7

42. Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011 Feb;67(2):249–254. https://doi.org/10.1007/s00280-010-1311-3

43. Lee K, Bang K, Yoo C, Hwang I, Jeong JH, Chang H-M, et al. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat. 2020 Jan;52(1):254–262. https://doi.org/10.4143/crt.2019.190

44. Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, et al. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers (Basel). 2020 Apr 30;12(5):1131. https://doi.org/10.3390/cancers12051131

45. Chae H, Jeong H, Cheon J, Chon HJ, Ryu H, Kim I-H, et al. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol. 2020;12:1–8. https://doi.org/10.1177/1758835920923424

46. de Jesus VHF, Camandaroba MPG, Calsavara VF, Riechelmann RP. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Ther Adv Med Oncol. 2020;12: 1–13. https://doi.org/10.1177/1758835920905408

47. Buwenge M, Macchia G, Arcelli A, Frakulli R, Fuccio L, Guerri S, et al. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. J Pain Res. 2018;11:2169–2178. https://doi.org/10.2147/JPR.S167994

48. Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May 3;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324

49. Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S,

50. Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317–326. https://doi.org/10.1016/S1470-2045(13)70021-4

51. Wang C, Liu X, Wang X, Wang Y, Cha N. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Sep;97(36):e12260. https://doi.org/10.1097/MD.0000000000012260

52. Хитрова А.Н., Болотина Л.В., Корниецкая А.Л., Москвичева Л.И. Проведение высокоинтенсивной фокусированной ультразвуковой терапии в рамках комбинированного лечения неоперабельной больной раком поджелудочной железы. Онкология. Журнал им. П.А.Герцена. 2020;9(1):50– 54. https://doi.org/10.17116/onkolog2020901150

53. Neuzillet C, Gaujoux S, Williet N, Bachet J-B, Bauguion L, Colson Durand L, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis. 2018;50(12):1257–1271. https://doi.org/10.1016/j.dld.2018.08.008

54. Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem J-L, Malka D, et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 2019;11:1–43. https://doi.org/10.1177/1758835919875568